Cargando…

Clinical effects of central antagonist of cholecystokinin-1 receptors GB-115 in patients with Generalized Anxiety Disorder

INTRODUCTION: The pilot clinical study of GB-115, a new peptide antagonist of central cholecystokinin-1 receptors, revealed that drug was clinically effective in patients with generalized anxiety disorder (GAD) at dose 6 mg daily. Here, we provide results of post-hoc analysis of changes of anxiety a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dorofeeva, O., Syunyakov, T., Metlina, M., Ivashkina, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564032/ http://dx.doi.org/10.1192/j.eurpsy.2022.981

Ejemplares similares

Impact of central antagonist of cholecystokinin-1 receptors GB-115 on cognitive functions in patients with Generalized Anxiety Disorder
por: Dorofeeva, O., et al.
Publicado: (2022)

Differences in the effects of anxiolytics bromodihydrochlorophenylbenzodiazepine and fabomotizole in patients with anxiety disorders in dependence on their individually-typological features
por: Dorofeeva, O., et al.
Publicado: (2022)

A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
por: Tucker, Robin D., et al.
Publicado: (2019)

Cholecystokinin Receptor Antagonist Suppresses Melanoma Growth by Inducing Apoptosis of Tumor Cells
por: Funakoshi, Atsuko, et al.
Publicado: (2022)

Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
por: Rabiee, Atoosa, et al.
Publicado: (2022)

Antiproliferative Effect of a Novel Cholecystokinin‐B/Gastrin Receptor Antagonist, YM022
por: Murayama, Tohru, et al.
Publicado: (1996)

The Excitatory Effect of Cholecystokinin on Colonic Motor Function via Cholecystokinin(1) Receptor
por: Jun, Jae Yeoul
Publicado: (2011)

Cholecystokinin Activation of Cholecystokinin 1 Receptors: a Purkinje Cell Neuroprotective Pathway
por: Orr, Harry T.
Publicado: (2022)

Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment
por: Malchiodi, Zoe X., et al.
Publicado: (2021)

Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma
por: Shivapurkar, Narayan, et al.
Publicado: (2023)

Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic
por: Jolly, Gurbani, et al.
Publicado: (2023)

Dual pathways of internalization of the cholecystokinin receptor
Publicado: (1995)

Pregabalin for the treatment of generalized anxiety disorder
por: Khallouk, A., et al.
Publicado: (2022)

Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence
por: Wen, Di, et al.
Publicado: (2012)

Productivity of the performance of visual perceptual tasks and symptom severity in patients with schizotypal disorder
por: Vinogradova, M., et al.
Publicado: (2021)

Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.
por: Watanapa, P., et al.
Publicado: (1993)

2772. HCMV gB Ectodomain Subunit and gB mRNA Vaccines Reduce AD-3 Immunodominance and Elicit More Durable Antibody Responses Than gB/MF59 Immunization
por: Nelson, Cody S, et al.
Publicado: (2019)

4119 Cholecystokinin (CCK) Receptor Antagonist Reverses Nonalcoholic Steatohepatitis (NASH) by Reducing Hepatic Macrophages and Inflammatory Cytokines
por: Gay, Martha, et al.
Publicado: (2020)

Serum cholecystokinin levels can be a predictive factor for difficult cholecystectomy: Decreased cholecystokinin receptor levels
por: Utku Yılmaz, Tonguç, et al.
Publicado: (2022)

Comparison of Metacognitions in Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, and Healthy Controls
por: Gundogmus, I., et al.
Publicado: (2022)

115 Immune Correlates of Protection in Rhesus Monkeys
por: Barouch, Dan
Publicado: (2014)

S115. SYMPTOM DOMAINS IN SCHIZOPHRENIA AND GENE POLYMORPHISMS
por: Peitl, Vjekoslav, et al.
Publicado: (2018)

Primary clinical testing of the questionnaire “Brief questionary of quality of anxiety” in patients with generalized anxiety disorder
por: Morozova, M., et al.
Publicado: (2022)

Sensitivity of cholecystokinin receptors to membrane cholesterol content
por: Desai, Aditya J., et al.
Publicado: (2012)

Permanent Photodynamic Activation of the Cholecystokinin 2 Receptor
por: Tang, Wen Zhu, et al.
Publicado: (2020)

Dress syndrome, gabapentin (GB) and autografts
por: Aranda, Carolina, et al.
Publicado: (2015)

Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A “Dimmer-Switch” Hypothesis
por: Ballaz, Santiago J., et al.
Publicado: (2021)

Bi-Directional Effect of Cholecystokinin Receptor-2 Overexpression on Stress-Triggered Fear Memory and Anxiety in the Mouse
por: Chen, Qian, et al.
Publicado: (2010)

115. Evaluation of the Clinical Impact of the T2MR for the Diagnosis of Bloodstream Infections
por: Seitz, Tamara, et al.
Publicado: (2019)

T115. REASONING BIAS, WORKING MEMORY PERFORMANCE, AND A TRANSDIAGNOSTIC PHENOTYPE OF AFFECTIVE DISTURBANCES AND PSYCHOTIC EXPERIENCES IN THE GENERAL POPULATION
por: Rauschenberg, Christian, et al.
Publicado: (2018)

Cholecystokinin and the hormone concept
por: Rehfeld, Jens F
Publicado: (2021)

Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells
por: Mjønes, Patricia, et al.
Publicado: (2017)

PS24. Neural Circuitry of Over-Generalization of Conditioned Fear in Generalized Anxiety Disorder
por: Cha, Jiook, et al.
Publicado: (2016)

Heteromerization of μ-opioid receptor and cholecystokinin B receptor through the third transmembrane domain of the μ-opioid receptor contributes to the anti-opioid effects of cholecystokinin octapeptide
por: Yang, Yin, et al.
Publicado: (2018)

Associations of neuroinflammatory parameters with clinical features in patients with mild cognitive impairment and dementia
por: Zorkina, Y., et al.
Publicado: (2022)

O11.5. EFFECTIVENESS OF COORDINATED SPECIALTY CARE FOR EARLY PSYCHOSIS
por: Galling, Britta, et al.
Publicado: (2018)

PS115. The Effect of Fluoxetine on Behaviors in Transient Forebrain Ischemic Gerbil
por: Li, Hua, et al.
Publicado: (2016)

Cholecystokinin and Panic Disorder: Reflections on the History and Some Unsolved Questions
por: Rehfeld, Jens F.
Publicado: (2021)

Evaluation of depression and anxiety control in greek patients with major depressive disorder with/without generalized anxiety disorder and cardiovascular disease–pronoi study
por: Papanastasiou, P., et al.
Publicado: (2021)

25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma
por: Gay, Martha Dee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rii7pkes5ado1673fbn9shkbeq